Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Etelcalcetide (Parsabiv) vs Sincalide (Kinevac)
An educational, source-based comparison of Etelcalcetide (Parsabiv) and Sincalide (Kinevac) — how each peptide works, what it's researched for, and what to know before going deeper.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Synthetic C-terminal octapeptide of cholecystokinin for gallbladder imaging.
Synthetic CCK-8 that binds CCK-A receptors on gallbladder smooth muscle, triggering contraction; used to assess gallbladder ejection fraction in cholescintigraphy.
- Gallbladder ejection fraction (HIDA scan)
- Pancreatic secretion testing
- Small bowel transit imaging
- • FDA-approved.
- • Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Etelcalcetide (Parsabiv) | Etelcalcetide vs cinacalcet | JAMA | 2017 | Non-inferior PTH reduction with IV administration. |
| Sincalide (Kinevac) | Standardized sincalide cholescintigraphy guideline | J Nucl Med | 2010 | Established 60-minute infusion as optimal for reproducible GBEF. |
Side-effect & safety grid
- FDA-approved.
- Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
- FDA-approved.
- Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Etelcalcetide (Parsabiv) vs Sincalide (Kinevac) — Key differences
- Class: Etelcalcetide (Parsabiv) is classified as Calcium-Sensing Receptor Agonist · Endocrine, while Sincalide (Kinevac) is CCK Analog · Diagnostics.
- Primary research focus: Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis; Sincalide (Kinevac) — gallbladder ejection fraction (hida scan).
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Diagnostics.